The TriClip system for edge-to-edge transcatheter tricuspid valve repair. A Spanish multicenter study.
Cardiopatía valvular
Heart failure
Heart valve diseases
Insuficiencia cardiaca
Insuficiencia cardiaca derecha
Insuficiencia tricuspídea
Reparación transcatéter de la válvula tricúspide
Right sided
Transcatheter tricuspid valve repair
Tricuspid regurgitation
Journal
Revista espanola de cardiologia (English ed.)
ISSN: 1885-5857
Titre abrégé: Rev Esp Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101587954
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
27
09
2021
accepted:
28
01
2022
pubmed:
16
3
2022
medline:
28
9
2022
entrez:
15
3
2022
Statut:
ppublish
Résumé
In patients with tricuspid regurgitation (TR), edge-to-edge transcatheter tricuspid valve repair (TTVR) is the strategy with the highest penetration worldwide. A dedicated edge-to-edge TTVR system has recently become available in Europe. The present study describes the initial experience with the system in Spain. This multicenter study collected individual data from the centers accepted for the use of the novel system within an initial limited release. Between June 2020 and March 2021, all patients undergoing an edge-to-edge TTVR using the TriClip system in Spain were included in the study. The primary endpoint was the achievement of a TR reduction of at least 1 grade at discharge. We included 34 patients. Most of them reported a previous history of atrial fibrillation (91%) and only 1 had a pacemaker lead. The primary endpoint (TR reduction of at least 1 grade at discharge) was met in all patients. Most of the patients required 1 (47%) or 2 clips (44%) with a clear predominance of XT (87%) over NT (13%). The location of the first clip was anteroseptal in >90% of the patients. Only 1 patient had a partial detachment, which was stabilized with additional clips in the same procedure. At discharge, TR severity was≤2 in 91% of patients. At 3 months, mortality was nil. Overall, 88% of patients were in New York Heart Association functional class≤2 and 80% had residual TR≤2. Edge-to-edge TTVR seemed to be effective and safe with a sustained TR reduction at 3 months. Further studies will be needed to confirm our findings.
Identifiants
pubmed: 35288060
pii: S1885-5857(22)00028-7
doi: 10.1016/j.rec.2022.01.007
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
797-804Informations de copyright
Copyright © 2022 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.